SEC Form 4 · accession 0000911916-16-000693
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Dallas
Officer — Chief Financial Officer
Period of report
Dec 1, 2016
Accepted (ET)
Dec 1, 2016 · 4:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Dec 1, 2016 | S | 1,473 | $35.1671 | D | 41,601 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.
- F2Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.